Exploring the prognostic landscape of oral squamous cell carcinoma through mitochondrial damage-related genes.

Publisher: BioMed Central Country of Publication: England NLM ID: 101319628 Publication Model: Electronic Cited Medium: Internet ISSN: 1755-8794 (Electronic) Linking ISSN: 17558794 NLM ISO Abbreviation: BMC Med Genomics Subsets: MEDLINE

Original Publication: London : BioMed Central

Mouth Neoplasms*/genetics ; Mouth Neoplasms*/pathology ; Carcinoma, Squamous Cell*/genetics ; Carcinoma, Squamous Cell*/pathology; Humans ; Prognosis ; Female ; Male ; Mitochondria/genetics ; Middle Aged ; Biomarkers, Tumor/genetics ; Gene Expression Regulation, Neoplastic ; Kaplan-Meier Estimate ; Nomograms

Oral squamous cell carcinoma (OSCC), the most prevalent form of oral cancer, poses significant challenges to the medical community due to its high recurrence rate and low survival rate. Mitochondrial Damage-Related Genes (MDGs) have been closely associated with the occurrence, metastasis, and progression of OSCC. Consequently, we constructed a prognostic model for OSCC based on MDGs and identified potential mitochondrial damage-related biomarkers. Gene expression profiles and relevant clinical information were obtained from The Cancer Genome Atlas (TCGA) database. Differential analysis was conducted to identify MDGs associated with OSCC. COX analysis was employed to screen seven prognosis-related MDGs and build a prognostic prediction model for OSCC. Cases were categorized into low-risk or high-risk groups based on the optimal risk score threshold. Kaplan-Meier (KM) analysis revealed significant survival differences (P < 0.05). Additionally, the area under the ROC curve (AUC) for patient survival at 1 year, 3 years, and 5 years were 0.687, 0.704, and 0.70, respectively, indicating a high long-term predictive accuracy of the prognostic model. To enhance predictive accuracy, age, gender, risk score, and TN staging were incorporated into a nomogram and verified using calibration curves. Risk scoring based on MDGs was identified as a potential independent prognostic biomarker. Furthermore, BID and SLC25A20 were identified as two potential independent mitochondrial damage-related prognostic biomarkers, offering new therapeutic targets for OSCC.
(© 2024. The Author(s).)

Front Oral Health. 2020 Jun 09;1:3. (PMID: 35047976)
BMC Med Genomics. 2022 Dec 24;15(1):269. (PMID: 36566175)
Mol Cancer. 2002 Dec 09;1:9. (PMID: 12513701)
Cancer. 2003 Aug 1;98(3):508-15. (PMID: 12879467)
Oncol Lett. 2014 Jul;8(1):7-11. (PMID: 24959211)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
Biochem Biophys Res Commun. 2015 Apr 17;459(4):574-8. (PMID: 25769954)
Acta Pharmacol Sin. 2022 Oct;43(10):2439-2447. (PMID: 35233090)
Diabetes Metab Syndr Obes. 2022 Dec 22;15:4001-4010. (PMID: 36582506)
Signal Transduct Target Ther. 2024 May 15;9(1):124. (PMID: 38744846)
Protein Sci. 2019 Nov;28(11):1947-1951. (PMID: 31441146)
Drug Discov Today. 2021 Jul;26(7):1689-1701. (PMID: 33737072)
J Cancer Res Clin Oncol. 2022 Sep;148(9):2169-2186. (PMID: 35501496)
Cell Death Dis. 2019 Feb 21;10(3):177. (PMID: 30792387)
Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33. (PMID: 27322403)
Oral Oncol. 2021 Oct;121:105451. (PMID: 34329869)
Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Nov;132(5):566-579. (PMID: 34518141)
Front Cell Dev Biol. 2021 Aug 05;9:687245. (PMID: 34422810)
J Transl Med. 2023 May 18;21(1):328. (PMID: 37198593)
Front Oncol. 2013 Dec 02;3:292. (PMID: 24350057)
J Cell Mol Med. 2021 May;25(9):4444-4454. (PMID: 33837652)
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592. (PMID: 36300620)
J Periodontal Res. 2020 Jan;55(1):13-22. (PMID: 31529626)
Cell Commun Signal. 2017 Dec 16;15(1):52. (PMID: 29246230)
Int J Mol Sci. 2023 Feb 01;24(3):. (PMID: 36769105)
Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Front Bioeng Biotechnol. 2020 Dec 08;8:618931. (PMID: 33425881)
Front Physiol. 2021 Mar 16;12:609770. (PMID: 33815132)
Redox Biol. 2021 Jun;42:101870. (PMID: 33509708)
Front Mol Biosci. 2023 Jan 17;10:1073770. (PMID: 36733434)
J Transl Med. 2024 Jan 4;22(1):21. (PMID: 38178094)
Cancers (Basel). 2022 Oct 10;14(19):. (PMID: 36230890)
J Oral Pathol Med. 2023 Jan;52(1):9-19. (PMID: 36380437)
Int J Mol Sci. 2023 Feb 11;24(4):. (PMID: 36835050)
Metabolomics. 2020 Sep 30;16(10):105. (PMID: 33000429)
J Natl Compr Canc Netw. 2020 Jul;18(7):873-898. (PMID: 32634781)
J Clin Invest. 2018 Aug 31;128(9):3682-3691. (PMID: 30168803)

WYRCQD2023028 Doctoral Research Initiation Fund of Wannan medical college; 2023AH010073 Program for Excellent Sci-tech innovation Teams of Universities in Anhui Province; 2024AMCD06 Anhui Province Engineering Research Center for dental materials and application; KJ2021ZD0103 Major Projects of Natural Science Research in Colleges and Universities in Anhui Province

Keywords: Comprehensive analysis; Mitochondrial damage; Oral squamous cell carcinoma; Prognosis

0 (Biomarkers, Tumor)

Date Created: 20240812 Date Completed: 20240812 Latest Revision: 20240815

20250114

PMC11321089

10.1186/s12920-024-01985-6

39134997